Clinical Trial Update: Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of ibrutinib in patients with relapsed or refractory transformed indolent B-cell non-Hodgkin lymphoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transformed Indolent B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2025-01-07